The health authorities specify that the Paxlovid treatment “is not authorized for the prevention of pre-exposure or post-exposure to Covid-19” and “does not replace vaccination”.
Article written by
Posted
Update
Reading time : 1 min.
The Pfizer laboratory’s Covid-19 pill was urgently authorized, Wednesday, December 22, by the United States Medicines Agency (FDA). It is an important step in the fight against the pandemic which could allow millions of patients to access treatment. “This authorization provides a new tool to fight Covid-19 at a crucial time in the pandemic, where new variants are emerging”, welcomed an official of the FDA, Patrizia Cavazzoni, quoted by a press release (link in English). It can be administered to high-risk patients over the age of 12, says the FDA.
The treatmentt “Paxlovid is available by prescription only and should be initiated as soon as possible after a diagnosis of Covid-19 and within five days of onset of symptoms”, specifies the United States Medicines Agency. She adds that he “is not authorized for pre-exposure or post-exposure prevention to Covid-19” and “does not replace vaccination”.